Want to see SYK full AI Analyst Report?
Top Page
Stryker
(NYSE:SYK)
Select Model
Select Model
Rating:73Outperform
Price Target:
$342.00
▲(3.74% Upside)
Action:Reiterated
Date:10/07/26
SYK scores well primarily on strong financial performance and a constructive earnings outlook (solid growth, margin expansion, narrowed guidance, and buyback resumption). The main constraint on the overall score is weak technical positioning (below key longer-term moving averages with negative MACD), while valuation sits in the middle due to a premium P/E and modest dividend yield.
Positive Factors
Organic growth and margin expansion
Stryker is combining high-single-digit organic growth with faster earnings expansion and improving margins. That operating leverage indicates strong execution and supports durable reinvestment in innovation, commercial coverage, and customer adoption over the next several quarters.
Negative Factors
Peripheral vascular disruption
The Inari disruption shows that operational issues in an important product area can directly reduce sales and create backlogs. Although management expects improvement by the end of Q3, recovery execution remains a risk to near-term growth and customer continuity.
Read all positive and negative factors
Positive Factors
Negative Factors
Organic growth and margin expansion
Stryker is combining high-single-digit organic growth with faster earnings expansion and improving margins. That operating leverage indicates strong execution and supports durable reinvestment in innovation, commercial coverage, and customer adoption over the next several quarters.
Read all positive factors
Stryker Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down Stryker’s revenue by region to show geographic concentration, sensitivity to local healthcare spending and procedure volumes, and which markets are fueling future expansion or posing risk.
Breaks down Stryker’s revenue by region to show geographic concentration, sensitivity to local healthcare spending and procedure volumes, and which markets are fueling future expansion or posing risk.
Data provided by:
The Fly
The FlyStryker (SYK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$117.81B
Dividend Yield1.15%
Average Volume (3M)2.69M
Price to Earnings (P/E)31.6
Beta (1Y)0.55
Revenue Growth8.48%
EPS Growth27.36%
CountryUS
Employees56,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)9.73
Shares Outstanding383,573,060
10 Day Avg. Volume2,604,293
30 Day Avg. Volume2,690,681
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue5.17
Enterprise Value/Gross Profit7.93
Enterprise Value/Ebitda19.95
Forecast
1Y Price Target
$364.72Price Target Upside10.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)14.96
Revenue Forecast (FY)$27.19B
Stryker Business Overview & Revenue Model
Company Description
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including ...
How the Company Makes Money
Stryker makes money primarily by selling medical devices, implants, and capital equipment to healthcare providers, generating revenue when products are delivered and accepted under customer contracts (with timing dependent on contract terms and ap...
Stryker Earnings Call Summary
Earnings Call Date:Jul 30, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call conveyed broad recovery and operational momentum: solid organic growth (9%), a strong adjusted EPS beat (+17.9%), expanding margins, record Mako performance, multiple product launches and healthy cash generation/backlog. Key negatives were an acute supply disruption in peripheral vascular (Inari) that drove a U.S. vascular decline (‑6.7%), lingering costs and absorption effects from the prior cybersecurity incident, and some launch timing variability. Management expects backorders to be manageable by end of Q3 and reiterated confidence in the full‑year outlook and capital demand, so positives materially outweigh manageable near‑term headwinds.Positive Updates
Strong overall organic sales growth
Company delivered 9% organic sales growth in Q2 2026 (9% U.S., ~8.9% international). Management narrowed full‑year organic net sales guidance to 8.3%–9.3%.
Negative Updates
Peripheral vascular (Inari) supply disruption and lost sales
U.S. vascular organic sales declined 6.7% in Q2 due to an operational disruption at an Inari plant that created meaningful backorders and lost sales. Management expects backorders to reach a manageable level by end of Q3. Analysts on the call estimated the drag to be roughly in the ~50–75 basis point range, and management said that estimate was 'in the ballpark.'
Read all updates
Q2-2026 Updates
Positive
Negative
Strong overall organic sales growth
Company delivered 9% organic sales growth in Q2 2026 (9% U.S., ~8.9% international). Management narrowed full‑year organic net sales guidance to 8.3%–9.3%.
Read all positive updates
Company Guidance
Stryker narrowed 2026 guidance to organic net sales growth of 8.3%–9.3% and adjusted net EPS of $14.95–$15.10 (with a modestly positive pricing impact and a slight FX tailwind if rates hold), after reporting Q2 organic sales growth of 9% and adjusted EPS of $3.69 (up $0.56, +17.9%); Q2 adjusted gross margin was 66% (+60 bps) and adjusted operating margin 27.4% (+170 bps). Management expects full‑year adjusted other income/expense of ≈$420M, a full‑year effective tax rate of 15%–16% (Q2: 16.5%), cash & marketable securities of ≈$3.5B and year‑to‑date cash from operations of $1.8B, and said peripheral vascular backorders should be manageable by end‑Q3. They reiterated confidence in a strong second half driven by elevated capital demand and production ramp, plan to resume share repurchases (≈$1B previously authorized) while keeping M&A the primary capital allocation priority.Stryker Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
74
Positive
Cash Flow
79
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.84B | 25.12B | 22.59B | 20.50B | 18.45B | 17.11B |
| Gross Profit | 16.84B | 16.07B | 14.54B | 12.49B | 11.04B | 10.71B |
| EBITDA | 6.69B | 6.31B | 6.01B | 5.06B | 4.02B | 3.61B |
| Net Income | 3.73B | 3.25B | 2.99B | 3.17B | 2.36B | 1.99B |
Balance Sheet | ||||||
| Total Assets | 47.93B | 47.84B | 42.97B | 39.91B | 36.88B | 34.63B |
| Cash, Cash Equivalents and Short-Term Investments | 3.48B | 4.10B | 4.49B | 3.05B | 1.93B | 3.02B |
| Total Debt | 14.94B | 16.36B | 14.12B | 13.49B | 13.53B | 12.90B |
| Total Liabilities | 23.94B | 25.42B | 22.34B | 21.32B | 20.27B | 19.75B |
| Stockholders Equity | 23.99B | 22.42B | 20.63B | 18.59B | 16.62B | 14.88B |
Cash Flow | ||||||
| Free Cash Flow | 4.70B | 4.28B | 3.49B | 3.14B | 2.04B | 2.74B |
| Operating Cash Flow | 5.53B | 5.04B | 4.24B | 3.71B | 2.62B | 3.26B |
| Investing Cash Flow | -1.45B | -4.87B | -3.00B | -962.00M | -2.92B | -859.00M |
| Financing Cash Flow | -3.04B | 113.00M | -525.00M | -1.59B | -749.00M | -2.37B |
Stryker Technical Analysis
Positive
329.67
Price Trends
295.20
Positive
308.51
Negative
323.56
Negative
Market Momentum
4.03
Negative
64.51
Neutral
86.71
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYK, the sentiment is Positive. The current price of 329.67 is above the 20-day moving average (MA) of 285.90, above the 50-day MA of 295.20, and above the 200-day MA of 323.56, indicating a neutral trend. The MACD of 4.03 indicates Negative momentum. The RSI at 64.51 is Neutral, neither overbought nor oversold. The STOCH value of 86.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYK.
Stryker Risk Analysis
Stryker disclosed 29 risk factors in its most recent earnings report. Stryker reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stryker Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $10.93B | 20.51 | 11.59% | ― | 19.74% | 51.10% | |
80 Outperform | $122.05B | 23.33 | 10.60% | 3.00% | 9.77% | 12.28% | |
73 Outperform | $117.81B | 31.57 | 16.36% | 1.15% | 8.48% | 27.36% | |
71 Outperform | $12.92B | 20.29 | 12.25% | 2.58% | 5.26% | 31.02% | |
71 Outperform | $18.80B | 23.86 | 6.36% | 0.97% | 8.62% | 0.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $926.27M | 70.98 | 1.24% | ― | 0.84% | ― |
* Healthcare Sector Average
SYK
Stryker
306.13
-73.38
-19.34%
IART
Integra Lifesciences
12.10
-3.83
-24.04%
MDT
Medtronic
94.79
3.68
4.04%
SNN
Smith & Nephew Snats
30.47
-5.27
-14.76%
ZBH
Zimmer Biomet Holdings
97.44
-4.59
-4.50%
GMED
Globus Medical
81.83
18.57
29.36%
Stryker Corporate Events
Business Operations and StrategyExecutive/Board Changes
Stryker Announces CEO Succession and Leadership Transition
Positive
Oct 6, 2026
On October 6, 2026, Stryker announced a planned leadership succession in which long-serving Chief Executive Officer Kevin Lobo will resign as CEO on December 31, 2026 and become Executive Chair of the Board on January 1, 2027. Spencer Stiles, curr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.